The CGRP story in migraine is one of the cleaner examples of mechanism-driven drug development actually working — researchers identified calcitonin gene-related peptide's role in migraine pathophysiology, validated it in dozens of studies over fifteen years, and then produced four injectable monoclonal antibodies and oral small-molecule antagonists that specifically block it. The result: migraine medicine went from beta-blockers and tricyclics (drugs repurposed from cardiovascular and psychiatric indications) to the first drugs designed specifically for migraine prevention. Now the trials are doing what follows success — finding the patients who don't respond to CGRP approaches, extending into migraine variants like cluster headache, and validating drug-free alternatives for the substantial population that can't or won't take preventive medications.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Four anti-CGRP monoclonal antibodies are FDA-approved for migraine prevention; all reduce monthly migraine days by 3–4 on average with ~50% of patients achieving ≥50% reduction. Atogepant (Qulipta) is the first oral daily gepant approved for chronic migraine prevention (PROGRESS trial: 5.1 fewer migraine days/month vs. 0.8 for placebo). Rimegepant has unique dual approval for both acute treatment and prevention. For cluster headache — one of the most painful conditions in medicine — galcanezumab reduced episodic cluster attacks significantly in ENFORCE; trials for chronic cluster headache are ongoing. Non-invasive neuromodulation devices (Nerivio, Cefaly, sTMS) now have Phase 3 evidence supporting their use as drug-free alternatives.
ClinicalMetric Analysis
- The 3–4 migraine day average reduction across CGRP antibodies conceals a clinically important response distribution that should inform trial design and prescribing decisions. The 25–30% of patients who achieve ≥75% reduction ("super-responders") are averaged together with non-responders who get 1 day reduction — producing a mean that doesn't describe either group accurately. At 12 weeks, non-responders to one CGRP antibody should switch mechanism rather than extend the trial. In clinical practice, this switching logic is applied inconsistently — many patients spend 6–12 months on a non-effective agent before trying a gepant or a different antibody that might have worked at 3 months.
- Rimegepant's dual acute + prevention approval in a single molecule reflects a genuine mechanistic insight about CGRP receptor occupancy thresholds — and helps patients plan their dosing around headache patterns. The same 75mg dose treats acute attacks (at headache onset, full CGRP receptor blockade) and prevents them (every-other-day dosing, sustained partial blockade). Understanding that CGRP occupancy above a threshold prevents headache initiation while the drug's presence below that threshold aborts an attack in progress — both using the same competitive antagonism mechanism — is pharmacologically informative for patients deciding whether to use rimegepant acutely, preventively, or both.
- Cluster headache requires mechanistic distinction from migraine at diagnosis — same trigeminal anatomy, different circuitry, and a different drug response profile that patients are frequently not told about early enough. Hypothalamic activation drives cluster headache's clockwork periodicity and ipsilateral autonomic symptoms; this is diagnostically distinguishing from migraine. Galcanezumab's ENFORCE result (8.7 fewer weekly cluster attacks vs. 5.2 placebo) is significant in a condition where the previous standard was oxygen and verapamil because nothing else worked. Patients with cluster headache frequently wait years for accurate diagnosis; anti-CGRP antibody eligibility should be assessed at initial evaluation by a headache specialist, not as a late-stage referral after first-line options have been exhausted.
The CGRP Monoclonal Antibodies: What the Data Actually Shows
CGRP is a neuropeptide released from trigeminal nerve terminals during migraine attacks. It causes vasodilation, sensitizes pain pathways, and its plasma levels correlate with migraine severity. CGRP levels rise during attacks and return to baseline with resolution — a clean mechanistic story that took 15 years to translate into drugs but eventually did so with four approved agents.
The four FDA-approved anti-CGRP antibodies for prevention: erenumab (Aimovig, targeting the CGRP receptor itself rather than the peptide), fremanezumab (Ajovy, quarterly or monthly dosing), galcanezumab (Emgality), and eptinezumab (Vyepti, administered intravenously quarterly). All reduce monthly migraine days by approximately 3–4 days vs. placebo, with ~50% of patients achieving ≥50% reduction — a standard responder definition in migraine trials. About 25–30% achieve ≥75% reduction ("super-responders"). These are well-tolerated drugs with minimal systemic effects, since IgG antibodies don't penetrate the CNS and CGRP's peripheral vascular effects are the primary safety concern.
What the 2026 trials are now asking: Can biomarkers (CGRP levels, PGI-M, calcitonin) predict which antibody will work best for a given patient? Do these drugs prevent chronification — the process by which episodic migraine (fewer than 15 headache days/month) becomes chronic (15 or more)? And does simultaneous CGRP antibody plus gepant create meaningful layered CGRP blockade?
Gepants: The Oral Preventive Option
Gepants are oral small-molecule CGRP receptor antagonists — fundamentally different from antibodies in their pharmacokinetics (short half-life, immediate onset, renally cleared) but with the same mechanistic logic. Importantly, gepants have no vasoconstrictive effects, making them usable in patients with contraindications to triptans — cardiovascular disease, stroke history, hemiplegic migraine, Raynaud's phenomenon.
Ubrogepant (Ubrelvy) and rimegepant (Nurtec ODT) are both approved for acute migraine. Rimegepant has the unique distinction of being approved for both acute treatment and preventive use on alternate-day dosing — the only oral drug with this dual indication. The COMMAND trial showed alternate-day rimegepant reduced migraine frequency by 4.3 days/month vs. 0.8 for placebo. The mechanism for prevention with an acute drug is interesting: sustained low-level CGRP receptor occupancy from frequent dosing appears to modify trigeminal sensitization over time.
Atogepant (Qulipta) is the most recently approved oral daily gepant specifically for episodic and chronic migraine prevention — the first drug in this mechanistic class designed explicitly for the preventive role. The ADVANCE trial (episodic migraine) showed 4.2 fewer migraine days/month at 10mg and 3.7 at 30mg vs. 1.6 for placebo. The PROGRESS trial (chronic migraine) showed 5.1 fewer migraine days at 60mg vs. 0.8 for placebo — a substantial separation. Active trials are comparing atogepant to CGRP antibodies in head-to-head design and evaluating it specifically in patients with medication-overuse headache who can't take triptans.
Cluster Headache: The Hardest Migraine-Spectrum Condition
Cluster headache causes attacks of excruciating unilateral periorbital pain — typically rated 10/10 — lasting 15–180 minutes, occurring in bouts of weeks to months (episodic) or continuously without remission periods (chronic). It's been called "suicide headache" for its severity. Historical treatment options were limited: sumatriptan injection and high-flow oxygen for acute attacks, verapamil and lithium for prevention. Neither is consistently effective and neither is mechanism-specific.
CGRP is elevated during cluster attacks — the same biology that drives migraine. Galcanezumab demonstrated significant reduction in cluster attack frequency in the ENFORCE trial for episodic cluster headache: cluster bout attack frequency fell from approximately 17 to 9 attacks per week in the active arm. However, ENFORCE was negative in chronic cluster headache, highlighting mechanistic or phenotypic differences between the subtypes that aren't fully understood.
Current cluster headache trial activity: eptinezumab (IV CGRP antibody) in Phase 3 for chronic cluster headache specifically; fremanezumab in both subtypes (PRISM trial testing high-dose during cluster periods); non-invasive vagus nerve stimulation (gammaCore) received FDA clearance based on ACT1 and ACT2 trial data showing acute relief in episodic cluster. Deep brain stimulation targeting the hypothalamus (the hypothalamus is activated during cluster attacks) remains investigational in chronic refractory cluster headache after promising open-label series.
Non-Invasive Neuromodulation: Drug-Free Alternatives with Real Evidence
For patients who want to avoid medication entirely — or who have cardiovascular contraindications, medication-overuse headache, or pregnancy — non-invasive neuromodulation devices now have clinical trial evidence backing their use:
Remote electrical neuromodulation (Nerivio)
A wearable arm device cleared by the FDA for both acute and preventive migraine. ACMR trial: 37% pain freedom at 2 hours vs. 18% for sham. PREMIUM trial (preventive use): 4.0 fewer monthly migraine days vs. 1.3 for sham. Works via conditioned pain modulation — stimulating arm afferents activates descending pain inhibitory pathways that modulate trigeminal pain processing. Particularly useful in cardiovascular patients who cannot use triptans or CGRP antibodies.
Single-pulse transcranial magnetic stimulation (sTMS, eNeura SpringTMS)
FDA-cleared for migraine with aura and chronic migraine. Phase 3 data showed 38% of patients pain-free at 2 hours vs. 17% for sham. The single magnetic pulse is believed to interrupt the cortical spreading depression that initiates migraine with aura. Best evidence is in patients with prominent aura who can use the device at aura onset before head pain begins.
External trigeminal nerve stimulation (Cefaly)
A forehead device stimulating the supraorbital and supratrochlear branches of the trigeminal nerve. PREMICE and ACME European randomized trials support preventive efficacy with a 20-minute daily protocol. FDA-cleared for both acute treatment and prevention. Multiple ongoing trials are comparing Cefaly to CGRP antibodies in patients with cardiovascular contraindications and evaluating combination strategies.
Key Takeaways
- Four CGRP monoclonal antibodies are approved for migraine prevention; ~50% of patients achieve ≥50% monthly migraine day reduction, with a meaningful super-responder (~25%) subgroup.
- Atogepant (Qulipta) offers oral daily preventive CGRP blockade for episodic and chronic migraine — PROGRESS showed 5.1 fewer migraine days/month vs. 0.8 for placebo in chronic migraine.
- Galcanezumab reduced episodic cluster headache attacks from ~17 to ~9/week in ENFORCE; chronic cluster headache remains without proven CGRP therapy and is the primary ongoing research target.
- Non-invasive devices (Nerivio, Cefaly, sTMS) have Phase 3 evidence and are particularly valuable for cardiovascular-risk patients and those seeking drug-free prevention approaches.
- Combination trials pairing CGRP antibodies with acute gepant therapy — layered CGRP blockade — are investigating whether simultaneous preventive and acute CGRP antagonism improves sustained response beyond either approach alone.